Anti-MDA5 antibody-positive dermatomyositis (MDA5+ DM) is frequently complicated by rapidly progressive interstitial lung disease (RP-ILD). The current study aims to identify predictors for the development of RP-ILD in MDA5+ DM, thereby providing an objective basis for early intervention strategies.
Keywords: anti-MDA5 antibody-positive dermatomyositis, biomarkers, meta-analysis, prediction, rapidly progressive interstitial lung disease
Rheumatology (Oxford, England)
Journal Article
English
42334960
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.